...
首页> 外文期刊>Postgraduate Medical Journal >MicroRNAs and liver disease: Viral hepatitis, liver fibrosis and hepatocellular carcinoma
【24h】

MicroRNAs and liver disease: Viral hepatitis, liver fibrosis and hepatocellular carcinoma

机译:MicroRNA与肝脏疾病:病毒性肝炎,肝纤维化和肝细胞癌

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

MicroRNAs (miRNAs), a type of highly conserved small non-coding RNAs with an average length of 22 nucleotides, may serve as major regulators of gene expression and indispensable components of cellular gene expression networks. They have critical roles in normal biological processes and have been linked to many tumours, including hepatocellular carcinoma (HCC). HCC is the fifth most common malignancy and the third leading cause of cancer-related death worldwide. Viral hepatitis, caused by infection with hepatitis B or C viruses (HBV or HCV), can increase the risk of HCC and contributes to a significant disease burden around the world. Because of the variety of molecular alterations that may arise during the development and progression of HCC, standard of care and treatment for patients with HCC remains unsatisfactory. MiRNAs have been shown to participate in the pathogenesis of both HBV and HCV. In addition to a role in pathogenesis, miRNAs have significant clinical value in the early diagnosis of HCC since they are present in the blood and can be used as diagnostic markers and potential targets for specific systemic treatment.
机译:MicroRNA(miRNA)是一种高度保守的小型非编码RNA,平均长度为22个核苷酸,可以作为基因表达的主要调节剂和细胞基因表达网络的必不可少的组成部分。它们在正常的生物学过程中起关键作用,并与许多肿瘤有关,包括肝细胞癌(HCC)。肝癌是全球第五大最常见的恶性肿瘤和第三大癌症相关死亡原因。由乙型或丙型肝炎病毒(HBV或HCV)感染引起的病毒性肝炎会增加HCC的风险,并给全世界带来巨大的疾病负担。由于在肝癌的发生和发展过程中可能会发生多种分子变化,因此肝癌患者的护理和治疗标准仍然不尽人意。 MiRNA已显示参与HBV和HCV的发病机制。除了在发病机理中起作用外,miRNA在肝癌的早期诊断中也具有重要的临床价值,因为它们存在于血液中,可以用作特定系统治疗的诊断标志物和潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号